The estimated Net Worth of Susan E Siegel is at least 2.78 百万$ dollars as of 17 May 2024. Ms. Siegel owns over 1,029 units of Illumina Inc stock worth over 977,419$ and over the last 14 years she sold ILMN stock worth over 538,770$. In addition, she makes 1,260,440$ as Independent Director at Illumina Inc.
Sign up
Ms. Siegel ILMN stock SEC Form 4 insiders trading
Susan has made over 10 trades of the Illumina Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently she exercised 1,029 units of ILMN stock worth 128,450$ on 17 May 2024.
The largest trade she's ever made was exercising 65,000 units of Illumina Inc stock on 10 August 2011 worth over 45,500$. On average, Susan trades about 2,618 units every 161 days since 2010. As of 17 May 2024 she still owns at least 7,830 units of Illumina Inc stock.
You can see the complete history of Ms. Siegel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Susan Siegel biography
Susan E. (Sue) Siegel is Director of the Company. Ms. Siegel has more than 30 years of corporate, entrepreneurial and venture capital experience. Before joining GE, she was a General Partner at Mohr Davidow Ventures, where she led investments in personalized medicine, digital health and life sciences. Prior to that, Ms. Siegel served as president and board member at Affymetrix, steering the company's transformation from a pre-revenue startup to a global genomics leader with a multibillion-dollar market cap. Earlier, she held executive positions spanning functional disciplines at Bio-Rad, DuPont and Amersham. Ms. Siegel has served on more than a dozen private and public corporate boards in her career, including Pacific Biosciences and Affymetrix. Currently, she is a board member at Align Technologies and MIT’s The Engine. In addition, she co-chairs Stanford Medicine’s Board of Fellows and serves on advisory boards for Harvard Partners Healthcare Innovation, UC Innovation Council, RAND Health Care, and USC Marshall School Board of Leaders. Her non-profit board appointments have included the National Venture Capital Association and Silicon Valley’s Tech Museum of Innovation.
What is the salary of Susan Siegel?
As the Independent Director of Illumina Inc, the total compensation of Susan Siegel at Illumina Inc is 1,260,440$. There are 6 executives at Illumina Inc getting paid more, with Mostafa Ronaghi having the highest compensation of 3,541,310$.
How old is Susan Siegel?
Susan Siegel is 59, she's been the Independent Director of Illumina Inc since 2019. There are 8 older and 14 younger executives at Illumina Inc. The oldest executive at Illumina Inc is John Thompson, 71, who is the Lead Independent Director.
What's Susan Siegel's mailing address?
Susan's mailing address filed with the SEC is C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065.
Insiders trading at Illumina Inc
Over the last 21 years, insiders at Illumina Inc have traded over 412,190,379$ worth of Illumina Inc stock and bought 13,386 units worth 1,243,499$ . The most active insiders traders include John Wendell Thompson、Jay T Flatley、Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of 954,700$. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth 991,676$.
What does Illumina Inc do?
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
What does Illumina Inc's logo look like?
Complete history of Ms. Siegel stock trades at Align Technology、Illumina Inc、Pacific Biosciences of California Inc、Nevro Corp
Illumina Inc executives and stock owners
Illumina Inc executives and other stock owners filed with the SEC include:
-
Mostafa Ronaghi,
Senior Vice President of Entrepreneurial Development -
Mark Van Oene,
Senior Vice President, Chief Commercial Officer -
Jay Flatley,
Executive Chairman of the Board -
Joydeep Goswami,
Senior Vice President - Corporate Development and Strategic Planning -
Charles Dadswell,
Senior Vice President, General Counsel, Secretary -
Francis deSouza,
President, Chief Executive Officer, Director -
Susan Siegel,
Independent Director -
Dr. Alexander Aravanis M.D., Ph.D.,
CTO & Head of Research and Product Devel. -
Aimee Hoyt,
Senior Vice President and Chief People Officer -
Sam A. Samad,
Chief Financial Officer -
Susan H. Tousi,
Chief Commercial Officer -
Sam Samad,
Chief Financial Officer, Senior Vice President -
Caroline Dorsa,
Independent Director -
John Thompson,
Lead Independent Director -
Robert Epstein,
Independent Director -
Gary Guthart,
Independent Director -
Frances Arnold,
Independent Director -
Philip Schiller,
Independent Director -
Jacquie Ross,
Vice President, Investor Relations -
Scott Gottlieb,
Independent Director -
Alex Aravanis,
Chief Technology Officer -
Phillip Febbo,
Senior Vice President, Chief Medical Officer -
Carissa Rollins,
Chief Information Officer -
Sallilyn Schwartz,
VP of Investor Relations -
Kevin Carl Pegels,
Chief of Global Operations -
Francis A. deSouza,
CEO & Director -
Charles E. Dadswell,
Sr. VP, Gen. Counsel & Sec. -
Juliet Cunningham,
VP of Investor Relations -
Steve Phillpott,
Sr. VP & Chief Information Officer -
Jose A. Torres Jr.,
Chief Accounting Officer & VP -
Robert P. Ragusa,
Chief Operations Officer -
Stephanie Campos,
Pres -
Kathryne Gambrell Reeves,
SVP, Chief Marketing Officer -
Daniel Bradbury,
Director -
A Blaine Bowman,
Director -
Omead Ostadan,
SVP Mktg, Prod & Strat Plan -
Karin Eastham,
Director -
Patricia Leckman,
SVP, Chief People Officer -
Malcolm Garret Hampton,
SVP Clinical Genomics Group -
Karen K Mcginnis,
VP, Chief Accounting Officer -
Jacob Thaysen,
Chief Executive Officer -
Robert P Ragusa,
SVP, Global Quality & Ops -
Susan H Tousi,
SVP, Chief Commercial Officer -
David R Walt,
Director -
William H Rastetter,
Director -
Nicholas Naclerio,
Sr VP, Corporate & Venture Dev -
Tristan Orpin,
VP Worldwide Sales -
Richard Klausner,
Sr VP, Chief Medical Officer -
Roy A Whitfield,
Director -
Jeff Huber,
Director -
Marc Stapley,
Sr VP & CFO -
Gerald Moeller,
Director -
Paul L Bianchi,
Sr VP, Human Resources -
Michel Bouchard,
Chief Accounting Officer -
Mark L Lewis,
Sr VP & GM Molecular Biology -
Gregory Heath,
Sr. VP and GM, Diagnostics -
Matthew L. Posard,
Sr VP & GM, Consumer Genomics -
Christian O Henry,
CFO, VP Finance -
Paul C Grint,
Director -
Christian Cabou,
Sr. VP and General Counsel -
Jack Goldstein,
Director -
Joel Mc Comb,
Sr. VP and GM, Life Sciences -
Stephen P Macmillan,
Director -
Alan Kersey,
V.P. & Site Manager -
John R Stuelpnagel,
VP Business Development -
John West,
Sr VP & GM DNA Sequencing -
David C Douglas,
Vice President Manufacturing -
Scott D Kahn,
Chief Information Officer -
Paulette D Cabral,
Vice President Human Resources -
Timothy M Kish,
VP Finance & CFO -
Arnold R Oliphant,
VP Scientific Operations -
R Scott Greer,
Director -
Arthur Holden,
Sr. VP Corp and Market Dev -
David L Barker,
Chief Scientific Officer -
Ventures Iii Lp Cw,
10% owner -
Clinton Bybee,
10% owner -
Keith Crandell,
10% owner -
Kirk Malloy,
V.P. of Customer Solutions -
George Poste,
Director -
Robert Nelsen,
Director -
Noemi C Espinosa,
VP Intellectual Property -
Robert C Kain,
Vice President Engineering -
Steven Lazarus,
10% owner -
Venture Fund Iii L P Arch,
10% owner -
Venture Partners Llc Arch,
10% owner -
Christensen Jakob Wedel,
SVP, Strategy/Corp Development -
Ankur Dhingra,
SVP, Chief Financial Officer -
Anna Richo,
Director -
Jose Torres,
VP, Chief Accounting Officer -
Kevin Carl Pegels,
Chief of Global Operations -
Scott B. Ullem,
Director -
Carissa Rollins,
SVP, Chief Information Officer -
John Edward Frank,
Chief Public Affairs Officer -
Steven Barnard,
SVP, Chief Technology Officer -
Scott D Ericksen,
VP, Chief Accounting Officer -
Everett Cunningham,
SVP, Chief Commercial Officer